NO973293L - Grönne porfyriner som immunmodulatorer - Google Patents

Grönne porfyriner som immunmodulatorer

Info

Publication number
NO973293L
NO973293L NO973293A NO973293A NO973293L NO 973293 L NO973293 L NO 973293L NO 973293 A NO973293 A NO 973293A NO 973293 A NO973293 A NO 973293A NO 973293 L NO973293 L NO 973293L
Authority
NO
Norway
Prior art keywords
immune modulators
green porphyrins
green
antigen
porphyrins
Prior art date
Application number
NO973293A
Other languages
English (en)
Other versions
NO973293D0 (no
Inventor
Agnes H Chan
David W C Hunt
Julia G Levy
Modestus O K Obochi
Anna M Richter
Guillermo O Simkin
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Publication of NO973293D0 publication Critical patent/NO973293D0/no
Publication of NO973293L publication Critical patent/NO973293L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F132/00—Homopolymers of cyclic compounds containing no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system
    • C08F132/08—Homopolymers of cyclic compounds containing no unsaturated aliphatic radicals in a side chain, and having one or more carbon-to-carbon double bonds in a carbocyclic ring system having condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Grønne porfyriner virker som antigen-spesiftkke immunmodulatorer i den aktive fasen til en immunrespons overfor et bestemt antigen, og interfererer med den intracellulære kommunikasjonen. Disse effektene oppstår i fravær av bestrålning som blir absorbert av grønn porfyrin.
NO973293A 1995-01-17 1997-07-16 Grönne porfyriner som immunmodulatorer NO973293L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/374,158 US5789433A (en) 1995-01-17 1995-01-17 Green porphyrins as immunomodulators
PCT/CA1996/000020 WO1996022090A1 (en) 1995-01-17 1996-01-11 Green porphyrins as immunomodulators

Publications (2)

Publication Number Publication Date
NO973293D0 NO973293D0 (no) 1997-07-16
NO973293L true NO973293L (no) 1997-09-16

Family

ID=23475554

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973293A NO973293L (no) 1995-01-17 1997-07-16 Grönne porfyriner som immunmodulatorer

Country Status (13)

Country Link
US (2) US5789433A (no)
EP (1) EP0794775A1 (no)
KR (1) KR100332554B1 (no)
CN (1) CN1198671A (no)
AU (1) AU706796B2 (no)
CZ (1) CZ291179B6 (no)
FI (1) FI972952A (no)
HU (1) HUP9801528A3 (no)
NO (1) NO973293L (no)
NZ (1) NZ298356A (no)
PL (1) PL321362A1 (no)
TW (1) TW384222B (no)
WO (1) WO1996022090A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
US6107325A (en) * 1995-01-17 2000-08-22 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US6096776A (en) * 1995-01-17 2000-08-01 Qlt Phototherapeutics, Inc. Green porphyrins as immunomodulators
US5834503A (en) * 1996-06-14 1998-11-10 Qlt Phototherapeutics, Inc. Methods to treat arterial plaque
EP0981371A1 (en) * 1997-05-16 2000-03-01 QLT Phototherapeutics, Inc. Green porphyrins as immunomodulators
CA2221912A1 (en) * 1997-11-21 1999-05-21 David Dolphin Photosensitizers with improved biodistribution and light-absorbing properties
US6428579B1 (en) * 1998-07-01 2002-08-06 Brown University Research Foundation Implantable prosthetic devices coated with bioactive molecules
US6364907B1 (en) 1998-10-09 2002-04-02 Qlt Inc. Method to prevent xenograft transplant rejection
WO2002064163A2 (en) 2001-02-15 2002-08-22 Qlt Inc. Reduction or prevention of pdt related inflammation
AU2002348477A1 (en) * 2001-05-01 2002-12-23 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
CA2449828A1 (en) * 2001-06-04 2003-01-16 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US20070020272A1 (en) * 2003-04-30 2007-01-25 Tayyaba Hasan Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use thereof
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
US20050048109A1 (en) * 2003-08-26 2005-03-03 Ceramoptec Industries, Inc. Non-polar photosensitizer formulations for photodynamic therapy
EP2644228A1 (en) 2007-06-27 2013-10-02 The General Hospital Corporation Method and apparatus for optical inhibition of photodynamic therapy
BRPI0907791A2 (pt) * 2008-02-27 2015-08-04 Yeda Res & Dev Conjugados rgd-(bacterio)clorofila para terapia fotodinâmica e formação de imagem de tumores necróticos
US7968127B2 (en) * 2008-07-28 2011-06-28 Winslow David E Reverse vitamin K effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
CN103127500B (zh) * 2013-02-07 2015-05-20 中山大学 卟啉色素作为免疫佐剂和疫苗的用途
CN110201162B (zh) * 2019-06-14 2021-09-07 中山大学附属第八医院（深圳福田） 光治疗剂在打破肿瘤免疫抑制微环境中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5171749A (en) * 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
US5087636A (en) * 1990-02-20 1992-02-11 University Of British Columbia Method to destroy malignant cells in mononuclear cell populations
FR2689888B1 (fr) * 1992-04-10 1994-06-10 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5422362A (en) * 1993-07-29 1995-06-06 Quadra Logic Technologies, Inc. Method to inhibit restenosis
CA2210109C (en) * 1995-01-13 2008-09-23 Quadra Logic Technologies Inc. Method to prevent transplant rejection
US5789433A (en) * 1995-01-17 1998-08-04 Quadra Logic Technologies, Inc. Green porphyrins as immunomodulators
WO1997009043A1 (en) * 1995-09-06 1997-03-13 The Research Foundation Of State University Of New York Two-photon upconverting dyes and applications

Also Published As

Publication number Publication date
FI972952A (fi) 1997-09-10
PL321362A1 (en) 1997-12-08
US6008241A (en) 1999-12-28
CZ221397A3 (en) 1997-11-12
JP3574456B2 (ja) 2004-10-06
HUP9801528A3 (en) 2000-02-28
FI972952A0 (fi) 1997-07-11
EP0794775A1 (en) 1997-09-17
NZ298356A (en) 2001-04-27
KR100332554B1 (ko) 2002-09-27
KR19980701484A (ko) 1998-05-15
AU706796B2 (en) 1999-06-24
CZ291179B6 (cs) 2003-01-15
US5789433A (en) 1998-08-04
TW384222B (en) 2000-03-11
WO1996022090A1 (en) 1996-07-25
AU4381996A (en) 1996-08-07
HUP9801528A2 (hu) 1998-10-28
CN1198671A (zh) 1998-11-11
NO973293D0 (no) 1997-07-16
MX9705376A (es) 1997-10-31
JPH10512268A (ja) 1998-11-24

Similar Documents

Publication Publication Date Title
NO973293L (no) Grönne porfyriner som immunmodulatorer
AU4841693A (en) Vaccines against group c neisseria meningitidis
ATE405243T1 (de) Säuglingspflegevorrichtung
FI953026A (fi) Menetelmä matkaviestimen käytt¦oikeuden hallitsemiseksi ja menetelmän toteuttava laitteisto
HK1034040A1 (en) Apo-2 ligand-anti-her-2 antibody synergism
EA200101075A1 (ru) Новый способ лечения
EA200500206A1 (ru) СПОСОБ И КОМПОЗИЦИИ ДЛЯ МОДУЛЯЦИИ РАЗВИТИЯ И ФУНКЦИИ КЛЕТОК Т-ХЕЛПЕРОВ (Тх)
CA2098105A1 (fr) Oligoside derive d'un polyoside antigenique issu d'un agent pathogene
NZ336196A (en) Use of green porphyrins for the treatment of secondary cataracts
DK159590A (da) To-trins-reduktionsventil, fortrinsvis til gasflasker
CA2210152A1 (en) Green porphyrins as immunomodulators
Bravo et al. On the role of equatorial coronal holes in cosmic ray modulation.
BG101526A (en) Antiphlogistic composition for external application
Cunningham The Baron and His Celestial Police
Smykov et al. Photometric study of AM Herculis.
McGraw The ZZ Ceti Stars-a New Class of Pulsating White Dwarfs.
Olivares The application of infrared speckle interferometry to the imaging of remote galaxies and AGN
Major et al. A note on the optical centre effects in the astrograph plate reduction.
Pulpan et al. Summary of Alaska earthquakes for the period July, August and September 1985
Kelsall et al. The COBE Diffuse Infrared Background Experiment Search for the Cosmic Infrared Background: II. Model of the Interplanetary Dust Cloud
AR005542A1 (es) Un transmisor en un sistema de comunicacion inalambrico.
Goryachev et al. Model of the photoelectric polarimeter for mapping the lunar polarization degree.
Malkan The Ionizing Flux from Star-Forming Galaxies
Lupie FGS1R Optimization
Vasil'Ev et al. The accuracy of the correction of smooth phase distortions using phase conjugation under the SBS of focused beams

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application